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Cover letter R2 AJD-D-12-00002 
 
Dear Dr. Sangüeza, dear Omar 
 
Enclosed please find the revised manuscript  " CD4/CD8 double negative mycosis fungoides 
with PD-1 (CD279) expression – a disease of follicular helper T cells?" (AJD-D-12-00002). 
We are very grateful for your comments and the comments of the reviewers. Enclosed 
please find the point-by-point answers to their comments. The corresponding changes in the 
manuscript has been highlighted by red.  
 
We hope that the revised manuscripts fulfills the requirements and very high standard for 
publication in the Journal. We very much appreciate your evaluation of our manuscript. 
 
Kind regards, 
Werner 
 
 
Point-by-point answers to the reviewer's comments 
 
Reviewer #1:  
(1) I am curious about the expression of PD-1 on various cells, and did not see this 
addressed in the report.  It may be beyond the scope of a case report, but is PD-1 
expression restricted to CD4 positive T cells and CD4-CD8 negative cells?  Is it ever seen on 
CD8 positive cells?  When?  Is it reported in other instances of CD4/CD8 negative T cells?  
What B cells express this? 
Reply: PD-1 expression can be induced in T-cells, B cells, and dendritic cells upon activation. 
In contrast, follicular T helper cells constitutiveky express PD-1 at high levels (Francisco et 
al. Immunol Rev 2010;236:219-242). To the best of our knowledge, PD-1 expression 
previously not been reported in CD4 CD8 double negative T-cells. A very recent publication 
(Baitsch et al. PLoS One. 2012;7(2):e30852. Epub 2012 Feb 8) reported expression of PD-1 
in CD8-positive T-cells. Expression of PD-1 by B-cells has been observed in the study by 
Xerri L et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and 
B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008; 
39:1050-8.This issue has been addressed in the revised rmanuscript on page 6, second 
paragraph.  
 
 
(2) I think the authors meant to say UVB "narrow band" rather than "barrow band." 
Reply: We apologize for this typographical error which was corrected in the revised 
manuscript.  
 
 
Reviewer #2:  
(1) This is a very interesting case that deserves publication. However, I believe this is a case 
of pagetoid reticulosis with a null-phenotype rather than conventional MF. The lesions are 
confined to the left leg and the histological pattern and immunophenotype are more 
consistent with PR than MF.  
Reply: The term pagetoid reticulosis according to current lymphoma classification is 
restricted to a unilesional form of MF. Thus we did not employ this term in our patient who 
had two separate lesions on the left lower leg.  
 
(2) PD-1 expression is not specific for FTH cells. High percentage of Sezary cells (about 2/3 
of cases) are PD-1 positive and PD-1 expression is also seen in other inflammatory 
conditions, especially viral infections. I believe bcl6/CD3 coexpression would be strong 
supporting data for the proposed origin of these cells.  
Reply: We fully agree that expression of PD-1 is not restricted or specific for CD4/CD8 
Cover Letter
double negative MF, since it is quite often seen in Sézary syndrome. Nevertheless, the 
expression of PD-1 in this unusual form of MF has not been described before and may shed 
light on the histogenesis of this variant. In our case, the PD-1 positive cells also express CD3 
and partially bcl-6. These findings demonstrate that they belong to follicular helper T cells. 
This information is provided on page 5, first paragraph of the revised manuscript. 
 
 
(3) "The lack of expression of CXCL-13 and CD10 as markers expressed by follicular T 
helper cells under physiological conditions may be suggestive of a possible origin of this 
unusual variant of MF from neoplastic follicular T helper cells." This sentence does not make 
any sense to me. 
 
Reply: The PD-1 positive cells in our case are the neoplastic cells. In neoplastic 
lymphocytes, a loss of markers is often found and may be a further argument for the 
neoplastic nature of the PD-1 cells. We changed the sentence to clarify this point on page 6 
last paragraph and page 7, first paragraph. 
 
 
(4) Please correct lymphoma not otherwise unspecified (NOS) on page 7, it should specified 
instead. 
Reply: This mistake has been corrected in the revised manuscript R2.  
 
(5) Page 4 should be "narrow band" rather than "barrow band" 
Reply: This typographical error was corrected in the revised manuscript.  
 
(6) We really don't need the names of topical steroid creams, but if you decide to keep them 
Mometasone furoate is misspelled twice. 
Reply: This error was corrected in the revised manuscript.  
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Abstract 
CD4/CD8 double negative mycosis fungoides (MF) is a rare phenotypic variant of this 
epidermotropic cutaneous T-cell lymphoma. Clinically, this MF form manifests with unusual 
appearances such as annular lesions confined to one body region like in our patient in whom 
the lesions were found on the left lower leg. The cellular origin of CD4/CD8 double negative 
MF is unknown. In our case, the intraepidermal CD4/CD8 double negative clonal T-
lymphocytes (CD2+, CD4-, CD8-, CD30-, betaF1+) expressed PD-1, but were negative for 
CXCL-13 and cytotoxic molecules (TIA-1, granzyme B, perforin). Our observation may give 
insight into the histogenesis of this unique MF variant and may also be of therapeutic 
significance since PD-1 may serve a target for therapeutic intervention.  
 
Key words: mycosis fungoides, cutaneous T-cell lymphoma, CD8, PD-1  
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Introduction 
Mycosis fungoides (MF) is the most common primary cutaneous lymphoma and shows a 
broad clinicopathologic as well as prognostic spectrum. (1), (2). CD4/CD8 double negative 
MF is a rare phenotypic variant. In a recent series, this double negative phenotype has been 
found in 18 (12%) of 140 patients with early stage MF. (3) Unusual clinical presentations 
including localized, hypopigmented and ichthyosiform have been observed to be 
overrepresented in that cohort. The authors of the original series discussed issues concerning 
the origin of CD4-CD8- neoplastic cells in MF as to whether they could represent a malignant 
counterpart of the normal subpopulation of lymphocytes or derive from antigen-driven T cells 
that lost expression of both markers. (3). Herewith we describe a MF patient with this peculiar 
immunophenotype and demonstrate that the CD4-CD8- in our case expressed the 
programmed death-1 (PD-1), an inhibitory member of the CD28 family located on 
chromosome 2q37. (4) PD-1 is expressed by a specific subset of T cells that are normally 
present in germinal centers with a helper function for follicular B cells (follicular helper T 
cells, TFH cells). These cells are characterized by a unique gene expression profile distinct 
from those of other naive, memory, and effector T helper subsets. (5) PD-1 expression is a 
characteristic feature of primary cutaneous CD4-positive small/medium-sized T-cell 
lymphoma  (CD4+ SMPTL) (6) and in angioimmunoblastic T-cell lymphoma. (7), (8)  We 
report for the first time the expression of PD-1 in CD4/CD8-double negative MF and discuss 
its significance. 
 
Material and methods 
Biopsy specimens were fixed in 10% buffered formalin and sections were routinely processed 
and embedded in paraffin. Serial 4 micrometer-thick sections were cut for hematoxylin and 
eosin stains as well as immunohistochemical stains. The antibodies used for 
immunohistochemistry included: CD2 (1:50, Novocastra/Leica-Microsystems, Heerbrugg, 
Switzerland), CD3 (1:75, Dako, Glostrup, Denmark), CD4 (1:2, Novocastra/Leica-
Microsystems, Heerbrugg, Switzerland), CD7 (1:25, Dako, Glostrup, Denmark), CD8 (1:400, 
Dako, Glostrup, Denmark), CD10 (1:100; Novocastra/Leica-Microsystems, Heerbrugg, 
Switzerland), CD20 (1:600, Dako, Glostrup, Denmark), CD30 (1:75; Novocastra/Leica-
Microsystems, Heerbrugg, Switzerland), CD45RO (RTU, Novocastra/Leica-Microsystems, 
Heerbrugg, Switzerland), CD45RA (1:100; Novocastra/Leica-Microsystems, Heerbrugg, 
Switzerland), CD56 (RTU, Novocastra/Leica-Microsystems, Heerbrugg, Switzerland), TIA-1 
(1:50, Immunotech Marseille, France), beta F1 (1:50, Thermo Scientific, Germany), TCR 
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gamma/delta (1:100, Thermo Scientific, Germany), PD-1 (1:10, developed by G. Roncador, 
MD PhD, Madrid, Spain), CXCL-13 (1:10; R&D Systems, Abingdon, UK), EBER in situ 
hybridization (RTU, Novocastra/Leica-Microsystems, Heerbrugg, Switzerland). Appropriate 
positive controls were included.  
 
Case Report 
A 70-year old woman presented with long-standing erythematous patches on the on the left 
lower leg (Fig. 1). The lesions had developed 5 years ago as slightly hypopigmented macular 
lesions. The annular erythematous margin had appeared 6 months before consultation. Family 
history revealed lymphocytic leukemia in a grandchild of the patient. The patient was treated 
for hypothyroidism, but otherwise was healthy. Due to accentuated margins and clinical 
resemblance to a fungal infection, the patient had been treated with topical antimycotics, with 
no success. Physical examination did not show enlarged lymph nodes. Results of hematologic 
examination of peripheral blood, serologic findings (LDH) as well as radiologic staging 
including computer tomography of the chest and abdomen did not reveal abnormalities. Patch 
testing performed in the phase of complete remission did not show delayed type 
hypersensitivity to standard allergens.  Following histopathological diagnosis, the patient was 
treated with UVB narrow band (311 nm) (three times per week) over a period of 10 weeks 
and topical steroids (mometasone furoate cream, once per day for 5 days per week) for 5 
weeks. This treatment resulted in complete remission. One month after the treatment has been 
finished, a local relapse with a solitary slightly infiltrated annular lesion on the left lower leg 
was observed with partially responded to topical steroids (halometasone cream) applied over a 
period of three weeks with partial remission. The patient discontinued treatment since she was 
afraid of side effects of topical steroids and since she was not disturbed by the disease. Stable 
disease with a persisting solitary annular lesion was observed during follow-up of 8 months.  
 
Histopathological findings 
The epidermis was slightly acanthotic, with variable degree of spongiosis. Discrete 
parakeratotic cornification was present (Fig. 2). The epidermis was heavily infiltrated by 
small lymphocytes with chromatin dense nuclei, some of them with irregular nuclear contours 
(Fig 3). In the upper dermis, the lymphoid infiltrate was mainly arranged around blood 
vessels, but additionally a focal interstitial component was present. Eosinophilic granulocytes 
and plasma cells were not found.  
 
Immunohistochemical features 
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Both intraepidermal and intradermal lymphocytes expressed CD2, CD3, and beta-F1, but 
intraepidermal lymphocytes were negative for CD4 and CD8 (Figs 4, 5). Approximately 70% 
of the intraepidermal lymphocytes expressed CD7. More than 90% of the intraepidermal 
lymphocytes expressed PD-1 and less than 10% showed reactivity for CXCL-13 (Fig 5). Bcl-
6 was expressed by 30% of the intraepidermal lymphocytes. The lymphocytes located in the 
epidermis were negative for CD45RO, whereas the dermal lymphocytes expressed CD45RO 
and CD4. CD8 and FOXP3 stained a few dermal lymphocytes, whereas no immunopositivity 
for the two markers was seen in the epidermal component. CD10, CD20, CD30, CD45RA, 
CD56 and TIA, perforin and granzyme B were not expressed. MUM1 labeled few 
lymphocytes both in the epidermal and dermal component. Staining for T-cell receptor (TCR) 
delta chain and in situ hybridization for EBV (EBER) were negative.  
 
Molecular biological assays 
T-cell receptor (TCR) rearrangement studies were performed using a multiplex polymerase 
chain reaction (PCR) with denaturing gradient gel electrophoresis as described elsewhere (9) 
and revealed a monoclonal rearrangement of TCR gamma genes.  
 
Discussion 
The spectrum of CD4/CD8 double negative cutaneous T-cell lymphomas reported in the 
literature encompasses MF, pagetoid reticulosis, gamma/delta-positive cutaneous T-cell 
lymphoma, HTLV-1 associated adult T-cell lymphoma/leukemia, and cases which can be 
classified as cutaneous peripheral T-cell lymphoma, unspecified according to the WHO 
classification (2008; 4th edition) (10), (11),  (12), (13), (14), (15)  . Less than 35 cases of 
CD4/CD8 double negative early MF have been reported since the first description in 1993 by 
Ralfkiaer and coworkers (16), (17),  (3) , (18), (19) Our case supports the observation of 
Hodak et al that CD4/CD8 double negative MF is often associated with an unusual clinical 
presentation as in our patient in whom CD4/CD8 double negative MF clinically presented 
with annular and centrally hypopigmented lesions confined to the left lower leg as one body 
region also referred to as localized MF. Except for the expression of CD30 in early MF, none 
of the phenotypic MF variants appears to be of prognostic significance. (20). Due to the fact 
that cases of CD4/CD8 double negative MF had not been recognized prior to their work, 
Hodak et al considered the possibility that this variant of MF might be unique to the Middle 
East. (3) Our patient is of Swiss origin. In conjunction with previous reports our observation 
confirms that CD4/CD double negative MF occurs also in countries of central/western 
Europe. (16), (17), (19).  
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In contrast to the majority of the previously reported cases of CD4/CD8 double negative MF 
cases, the intraepidermal CD4 and CD8 negative tumor cells in our patient did not express 
cytotoxic molecules (TIA-1, granzyme B, perforin) indicating that the tumor cells do not 
belong to cytotoxic T-cells. The classic CD4+ form of MF is considered to represent a 
neoplasm derived from memory T helper cells. (21) The cellular origin of CD4/CD8 double 
negative MF, however, is unknown. In our case, the intraepidermal CD4/CD8 double negative 
clonal lymphocytes expressed PD-1. PD-1 expression in CTCL including MF has little been 
investigated to date and the results appear controversial. Roncador et al found PD-1 positivity 
was found in 4 out of 5 cases (80%). In contrast, Wada et al detected PD-1 immunoreactivity 
only 15 of 30 MF cases (50%). (8), (22) In two most recent articles, Cetinözman et al. 
reported PD-1 in only a subset of 2 out of 21 MF cases (9%) (23), whereas Kantekure et al 
detected PD-1 positive T cells  in all 9 patch and plaque MF cases, with 7 of the 9 cases 
showing more than 25% of the atypical lymphocytes expressing PD-1. (24) These differences 
may be due to different antibodies and immunohistochemical protocols well as due to 
different cut-off levels for positivity. There was no specification as to whether these cases 
manifested the usual and most common CD4+CD8- phenotype.  
 
Expression of PD-1 characterizes follicular helper T cells (TFH), which are normally present in 
germinal centers and possess helper function for B-cells. (4) PD-1 may be expressed on 
activated T cells and B cells (25),  (26). PD-1 is a negative regulator of T cell activation and 
proliferation that mediates suppressive action by binding to its ligands PD-L1 and PD-L2. 
(27) In the context of lymphomas, PD-1 cells have been found to be expressed in nodal 
angioimmunoblastic T-cell lymphoma and in primary cutaneous lymphomas classified as 
CD4+SMPTL and identical lesions diagnosed by others as pseudolymphomatous folliculitis 
or nodular T-cell pseudolymphoma. (7), (28), (6) It can be speculated that CD4/CD8 double 
negative MF represents a neoplastic counterpart of TFH cells. Alternatively, expression of PD-
1 may be upregulated as the result of activation of antigen-stimulated T cells with loss of CD4 
and CD8 since PD-1 can be expressed on activated T-cells. Remarkably, the PD-1 positive 
tumor cells in our case did not show expression of CXCL-13 and bcl-6 only in 30%, whereas 
tumor cells in cutaneous CD4+ SMPTL express both markers. (6) Neoplastic lymphocytes 
may show a loss of markers expressed by their normal counterparts under physiological 
conditions. Thus the lack of expression of CXCL-13 and CD10 as markers in our case could 
argue for the neoplastic nature of the PD-1 positive lymphoid cells. We hypothesize that this 
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CD4/CD8 double negative unusual variant of MF may derive from neoplastic follicular T 
helper cells. 
  
The CD4/CD8 double negative phenotype in MF appears to have no prognostic significance, 
as so far reported cases showed an indolent course. (3) This is important as the differential 
diagnosis includes a heterogeneous group of other CTCL with CD4/CD8 double negative 
phenotype characterized by an aggressive clinical course. (13) Based on the clinical, 
histological and phenotypic findings, cutaneous gamma/delta lymphoma, peripheral T-cell 
lymphoma, not otherwise specified (NOS), and infiltrates of angioimmunoblastic T-cell 
lymphoma could be excluded as differential diagnoses in our patient. The absence of 
eosinophilic granulocytes, the negative patch test, the phenotype of lymphocytes as well as 
the detection of clonal T-cells argue against lymphomatoid contact dermatitis.  
 
Although our observation is limited to a single case, it may give insight into the histogenesis 
of this MF variant and indicate the direction for future studies in the field. The findings will 
also be of therapeutic significance since PD-1 may serve as an interesting target for 
therapeutic intervention. (27) 
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Figure legends: 
 
Figure 1: 
Annular and hypopigmented patches on the left lower leg. 
 
Figure 2: 
Epidermis infiltrated by small lymphocytes with chromatin dense nuclei. H&E, original 
magnification, 100X 
 
Figure 3: Intraepidermal lymphocytes show nuclear atypia. H&E, original magnification, 
200X 
 
Figure 4: 
Both intraepidermal and intradermal lymphocytes express CD3, Immunohistochemistry, 
original magnification, 100X 
 
Figure 5: 
A. Intraepidermal and intradermal lymphocytes express beta-F1. B. Lack of expression of 
CD4 by intraepidermal lymphocytes. C. Intraepidermal lymphocytes are negative for 
CD8. D. Intraepidermal lymphocytes express PD-1. (Immunohistochemistry, original 
magnification, 100X A-D) 
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Dear Dr. Sangüeza, dear Omar 
 
Enclosed please find the revised manuscript  " CD4/CD8 double negative mycosis fungoides 
with PD-1 (CD279) expression – a disease of follicular helper T cells?" (AJD-D-12-00002). 
We are very grateful for your comments and the comments of the reviewers. Enclosed 
please find the point-by-point answers to their comments. The corresponding changes in the 
manuscript has been highlighted by red.  
 
We hope that the revised manuscripts fulfills the requirements and very high standard for 
publication in the Journal. We very much appreciate your evaluation of our manuscript. 
 
Yours sincerely, 
Werner Kempf 
 
 
Point-by-point answers to the reviewer's comments 
Reviewer #1: This is an intriguing report of a case of mycosis fungoides with an unusual 
immunophenotype, drawing attention to the potential expression of PD-1 in such cases.   
 
(1) Abstract last sentence:  "This is the first report of PD-1 expression in a CD4/CD8 double 
negative MF."   This statement immediately led me to question how often PD-1 is expressed 
in otherwise ordinary MF.  The most recent issue of the American Journal of Surgical 
Pathology addresses this very question, and likely came out in print after the current paper 
was submitted.  In the AJSP report, 2 of 21 cases of MF showed PD-1 expression, with 
expression of CXCL13 and bcl6, and with a CD4+ phenotype.  Additionally according to 
Reference 23 in that journal (referring to Am J Hematol 2011;86:325-7) a full 50% of 
otherwise typical MF express PD-1.  Therefore, its expression in this double negative 
example may not be so extraordinary, albeit interesting.  Since these reports just came out, 
perhaps a brief mention should be incorporated in the current case report? 
 
Reply: We very much appreciate this comment. In fact, both papers mentioned by the 
reviewer were discussed and cited in the original version (refs 22 and 23 in the revised 
version). As seen from these papers, the data on PD-1 in MF are controversial. Whereas the 
study Cetinötzman et al published in Am J Surg Pathol found expression of PD-1 in only 2 
out of 21 MF cases, the other study by Wada et al. reported PD-1 expression in 15 out of 30 
MF cases (50%). There is an additional study just published in the February issue of the 
Journal (Am J Dermatopathol 2012 Feb;34(1):126-8) after submission of our manuscript. 
Kantekure et al. described PD-1 positive T-cells was detected in all 9 patch and plaque 
cases; in 7 of the 9 cases, more than 25% of the atypical lymphocytes expressed PD-1. 
These differences may be due to different antibodies and immunohistochemical protocols as 
well as due to different cut-off levels for positivity. In only a small subset, more than 50% of 
cells expressed PD-1. In our case, all intraepidermal tumor cells were positive. We added 
this point to the discussion including the results of above mentioned studies and the 
corresponding references (ref 24).  
 
(2) Why did the authors add PD-1 staining to their profile of this double negative MF?  The 
clinical features seem to fit MF despite absence of CD4 or CD8. I might not have thought to 
do this stain, and wonder what triggered the idea. 
 
Reply: We are currently performing studies on PD-1, FOXP3 as well as other T-cell markers 
in various CTCL. Due to the very unusual phenotype of our case, we hypothesized that these 
cells may represent a neoplastic counterpart of one of the above mentioned T-cell subsets 
and were positively suprised to find expression of PD-1 by all the CD4 CD8 double negative 
tumor cells.  
Cover Letter
 
(3) Case report:  Toward the end of the case report, the authors mention "a relapse was 
observed."  Please clarify, do you mean at the same site? 
 
Reply: The relapse occurred at the same site (left lower leg). This point has been added to 
the section Case report in the revised version.  
 
(4) Figures are crisp.  For some reason Figure 2 is blurry on the computer screen, but when 
the high-resolution image was downloaded, it looked fine.  
 
Reply: We are grateful for this comment. We checked figure 2 again and did not find it non-
pixeled. The figure has a 300dpi resolution.  
 
(5) Figure 5 is impressive, we have trouble getting such a good result from beta F1. Also 
interesting the authors stained with the (new?) antibodies to gamma delta T cells.   
 
Reply: We stained for beta F1 and TCR delta 1 which showed reactivity of almost all CD4 
CD8 double negative cells for beta F1, but no expression of TCR delta 1. The absence of 
TCR delta 1 expression has been added to the results in the revised manuscript. Whereas 
betaF1 gives stable and reproducible staining results, the new antibody against the 
gamm/delta T-cell receptor (clone 1.302) is challenging. The clone/diluation/source are 
indicated in the manusrcipt and we will be happy to provide more information if needed.  
 
(6) Immunohistochemical features:   
There may be a word missing in the sentence:  "The lymphocytes located in the epidermis, 
CD45RO, whereas the dermal lymphocytes expressed CD45RO."   Do you mean the 
intraepidermal cells were negative for CD45RO? 
 
Reply: We apologize for this incomplete sentence. As suggested by the reviewer, the 
corrected sentence is: ""The lymphocytes located in the epidermis were negative for 
CD45RO, whereas the dermal lymphocytes expressed CD45RO."  
 
(7) Discussion page 6 middle:  "PD-1 is expressed on activated T cells and B cells."  Is 
expression restricted to CD4 positive T cells?  Is it ever seen on CD8 positive cells?  When? 
 Is it reported in other instances of CD4/CD8 negative T cells?  
 
Reply: To the best of our knowledge, PD-1 expression has previously not been reported in 
CD4 CD8 double negative T-cells. A very recent publication (Baitsch et al. PLoS One. 
2012;7(2):e30852. Epub 2012 Feb 8) reported expression of PD-1 in CD8-positive T-cells.  
 
Discussion  last paragraph:  The authors cite a differential diagnosis of cutaneous 
gamma/delta lymphoma, peripheral T cell lymphoma, and angioimmunoblastic lymphoma. 
 Should another be added to this list, small/medium pleomorphic T cell lymphoma?  Does the 
absence of CD4 expression preclude this?  Perhaps a word of clarification here. 
 
Reply: We did not add small/medium pleomorphic T cell lymphoma to the list, since this 
entity shows absence or only very subtle and focal epiderotropism of lymphocytes, whereas 
our case was charactreized by prominent epidermotropism. In addition, the tumor cells in 
small/medium pleomorphic T cell lymphoma express CD4 which was not expressed in the 
case we report. Due to these two aspects, we did not add small/medium pleomorphic T cell 
lymphoma to the list of differential diagnoses.  
 
 
Reviewer #2:  
 
(1) The hypothesis proposed by the authors that PD-1 expression probably implies a 
follicular TH  (FTH) cell population is flawed.  By definition FT "helper cells" are CD4 positive 
and for the most part bcl6, CXCL-13 and other markers like CD200 should also be 
expressed.  
 
Reply: The PD-1 positive cells in our case are neoplastic cells. In neoplastic cells a marker 
loss is often found and may even argue for the neoplastic nature of the PD-1 cells. The PD-1 
positive cells in our case partially expressed bcl-6 and CXCL-13 (30% and 10%, 
respectively) of the intraepidermal CD4 CD8 double negative cells indicating that the PD-1 
positive tumor cells partially retained the phenotype of their physiological or normal 
counterpart.  
 
 
(2) In my opinion, based on the localized presentation of the lesions to the lower extremities 
with illustrations showing a pagetoid pattern with double negative expression, the most 
accurate diagnosis should be pagetoid reticulosis which often shows a distinct intraepidermal 
phenotype with CD8+ or double negative phenotype.   
 
Reply: Since the term pagetoid reticulosis according to the current lymphoma classifications 
is restricted to a unilesional form of MF, we did not employ this term in our patient who had 
two separate lesions on the left lower leg.  
 
 
(3) As the authors mentioned,  PD-1 is an activation marker and it's also often expressed in 
subsets of CTCL, especially Sezary syndrome, not necessarily associated with a FTH 
phenotype.  Intraepidermal expression of PD-1 cells probably reflects an activated 
phenotype, albeit CD30 negative. CD25 could also be checked as an alternative.  Since viral 
infections tend to express PD-1, EBER or LNP-1 should be considered. 
 
Reply: Remarkably, less than 10% of the PD-1 positive showed reactivity for CXCL-13 and 
bcl-6 was expressed by 30% of the intraepidermal PD-1 positive lymphocytes. This lack of 
additional markers, i.e. antigen loss, is a common phenomenon in T-cell lymphoma. This 
observation may support the hypothesis that the CD4 CD8 double negative tumor cells in this 
MF variant are the (neoplastic) counterpart of PD-1 cells characterized by antigen loss for 
CXCL-13 and bcl-6 due their neoplastic nature. Despite the tumor cells did not express 
CD25., the partial expression of MUM-1 may indicate that the tumor cells in our case carry 
features of activated T-cells. These informations were added to the revised manuscript.  
In situ hybridization for EBV (EBER) was negative as mentioned in the text.  
 
(4) In the discussion section the phrase "The lack of expression of CXCL-13 and CD10?may 
be suggestive of FTH cells" is a bit confusing since both of these markers should be 
expressed in FTH cells.  
 
Reply: Please see comment to point 1.  
 
(5) CD7 expression is also not typical of FTH, AITL is mostly CD7 negative. 
 
Reply. We agree with this comment. We examined CD7 since in MF the intraepidermal cells 
often exhibit loss of CD7.  
 
 
(6) Hypothyreosis is an unfamiliar term in the US, suggest hypothyroidism instead. 
 
Reply: The term was corrected in the revised manuscript as suggested by the reviewer.  
 
Reviewer #3:  
This is an interesting observation on a patient with mycosis fungoides (MF). 
 
1) There should be less emphasys on pathogenetic and therapeutic possibilities related to 
PD-1 expression, as this is a single case report. A recent publication showed that PD-1 is not 
commonly expressed in early MF (ref. 22 in the present manuscript). 
 
Reply: In regard to the development of personalized targeted therapy in oncology, the 
expression of PD-1 and other markers may be of therapeutic relevance even if only a subset 
of cases shows expression of such markers. Moreover, very recent publications show 
controversial data on the prevalence of PD-1 expression in MF (see comment 1 to reviewer 
1). Therefore, we would like to mention the potential link of PD-1 as a target for therapeutic 
interventions.  
 
2) PD-1 may be expressed also by cells other than follicular T-helper lymphocytes. 
 
Reply: A few other lymphocytic subsets such as CD8 positive T-cells have been reported to 
express PD1 (please see also point 7 in the comments of reviewer no. 1).  
 
3) There are more than 32 cases of CD4-/CD8- MF in the literature; a manuscript on large 
numbers of MF with phenotypic features should be cited and added to the reference list (Br J 
Dermatol 2008;159:881-886). There are several other cases in isolated reports - it should be 
more clearly stated that the suggestion that this is a "geographical" variant is devoid of any 
support. 
 
Reply: We are grateful for this information. The reference in which 2 double negative cases 
of mycosis fungoides were inlcuded (Br J Dermatol 2008;159:881-886) has now been cited in 
the revised version of the manuscript (Ref 19). Following the statments of the reviewer that 
"There are more than 32 cases of CD4-/CD8- MF in the literature and There are several 
other cases in isolated reports ",  we have also checked once again the literature and found 
only one additional reference  - Ralfkiaer E 1994. This paper has now been included in the 
revsied manuscript.  
 
The reviewer is right in indicating that the suggestion the disease in question is not a 
geographical MF variant and this is exactly what we are saying. However, when Hodak et al 
made this suggestion, it was quite logical given their data.    
 
4) the pictures are of very good quality; however, figure 4 can be omitted; figures 5-8 should 
be put in a panel. 
 
Reply: Figure 4 demonstrates expression of the pan T-cell marker CD3 by the tumor cells. 
Thus we would prefer to keep this fugure. We followed the suggestion of the reviewer to put 
figures 5-8 into a composite panel.  
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Abstract 
CD4/CD8 double negative mycosis fungoides (MF) is a rare phenotypic variant of this 
epidermotropic cutaneous T-cell lymphoma. Clinically, this MF form manifests with unusual 
appearances such as annular lesions confined to one body region like in our patient in whom 
the lesions were found on the left lower leg. The cellular origin of CD4/CD8 double negative 
MF is unknown. In our case, the intraepidermal CD4/CD8 double negative clonal T-
lymphocytes (CD2+, CD4-, CD8-, CD30-, betaF1+) expressed PD-1, but were negative for 
CXCL-13 and cytotoxic molecules (TIA-1, granzyme B, perforin). Our observation may give 
insight into the histogenesis of this unique MF variant and may also be of therapeutic 
significance since PD-1 may serve a target for therapeutic intervention.  
 
Key words: mycosis fungoides, cutaneous T-cell lymphoma, CD8, PD-1  
 3 
 
Introduction 
Mycosis fungoides (MF) is the most common primary cutaneous lymphoma and shows a 
broad clinicopathologic as well as prognostic spectrum. (1), (2). CD4/CD8 double negative 
MF is a rare phenotypic variant. In a recent series, this double negative phenotype has been 
found in 18 (12%) of 140 patients with early stage MF. (3) Unusual clinical presentations 
including localized, hypopigmented and ichthyosiform have been observed to be 
overrepresented in that cohort. The authors of the original series discussed issues concerning 
the origin of CD4-CD8- neoplastic cells in MF as to whether they could represent a malignant 
counterpart of the normal subpopulation of lymphocytes or derive from antigen-driven T cells 
that lost expression of both markers. (3). Herewith we describe a MF patient with this peculiar 
immunophenotype and demonstrate that the CD4-CD8- in our case expressed the 
programmed death-1 (PD-1), an inhibitory member of the CD28 family located on 
chromosome 2q37. (4) PD-1 is expressed by a specific subset of T cells that are normally 
present in germinal centers with a helper function for follicular B cells (follicular helper T 
cells, TFH cells). These cells are characterized by a unique gene expression profile distinct 
from those of other naive, memory, and effector T helper subsets. (5) PD-1 expression is a 
characteristic feature of primary cutaneous CD4-positive small/medium-sized T-cell 
lymphoma  (CD4+ SMPTL) (6) and in angioimmunoblastic T-cell lymphoma. (7), (8)  We 
report for the first time the expression of PD-1 in CD4/CD8-double negative MF and discuss 
its significance. 
 
Material and methods 
Biopsy specimens were fixed in 10% buffered formalin and sections were routinely processed 
and embedded in paraffin. Serial 4 micrometer-thick sections were cut for hematoxylin and 
eosin stains as well as immunohistochemical stains. The antibodies used for 
immunohistochemistry included: CD2 (1:50, Novocastra/Leica-Microsystems, Heerbrugg, 
Switzerland), CD3 (1:75, Dako, Glostrup, Denmark), CD4 (1:2, Novocastra/Leica-
Microsystems, Heerbrugg, Switzerland), CD7 (1:25, Dako, Glostrup, Denmark), CD8 (1:400, 
Dako, Glostrup, Denmark), CD10 (1:100; Novocastra/Leica-Microsystems, Heerbrugg, 
Switzerland), CD20 (1:600, Dako, Glostrup, Denmark), CD30 (1:75; Novocastra/Leica-
Microsystems, Heerbrugg, Switzerland), CD45RO (RTU, Novocastra/Leica-Microsystems, 
Heerbrugg, Switzerland), CD45RA (1:100; Novocastra/Leica-Microsystems, Heerbrugg, 
Switzerland), CD56 (RTU, Novocastra/Leica-Microsystems, Heerbrugg, Switzerland), TIA-1 
(1:50, Immunotech Marseille, France), beta F1 (1:50, Thermo Scientific, Germany), TCR 
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gamma/delta (1:100, Thermo Scientific, Germany), PD-1 (1:10, developed by G. Roncador, 
MD PhD, Madrid, Spain), CXCL-13 (1:10; R&D Systems, Abingdon, UK), EBER in situ 
hybridization (RTU, Novocastra/Leica-Microsystems, Heerbrugg, Switzerland). Appropriate 
positive controls were included.  
 
Case Report 
A 70-year old woman presented with long-standing erythematous patches on the on the left 
lower leg (Fig. 1). The lesions had developed 5 years ago as slightly hypopigmented macular 
lesions. The annular erythematous margin had appeared 6 months before consultation. Family 
history revealed lymphocytic leukemia in a grandchild of the patient. The patient was treated 
for hypothyroidism, but otherwise was healthy. Due to accentuated margins and clinical 
resemblance to a fungal infection, the patient had been treated with topical antimycotics, with 
no success. Physical examination did not show enlarged lymph nodes. Results of hematologic 
examination of peripheral blood, serologic findings (LDH) as well as radiologic staging 
including computer tomography of the chest and abdomen did not reveal abnormalities. Patch 
testing performed in the phase of complete remission did not show delayed type 
hypersensitivity to standard allergens.  Following histopathological diagnosis, the patient was 
treated with UVB barrow band (311 nm) (three times per week) over a period of 10 weeks 
and topical steroids (momentasone furoat cream, once per day for 5 days per week) for 5 
weeks. This treatment resulted in complete remission. One month after the treatment has been 
finished, a local relapse with a solitary slightly infiltrated annular lesion on the left lower leg 
was observed with partially responded to topical steroids (halometasone cream) applied over a 
period of three weeks with partial remission. The patient discontinued treatment since she was 
afraid of side effects of topical steroids and since she was not disturbed by the disease. Stable 
disease with a persisting solitary annular lesion was observed during follow-up of 8 months.  
 
Histopathological findings 
The epidermis was slightly acanthotic, with variable degree of spongiosis. Discrete 
parakeratotic cornification was present (Fig. 2). The epidermis was heavily infiltrated by 
small lymphocytes with chromatin dense nuclei, some of them with irregular nuclear contours 
(Fig 3). In the upper dermis, the lymphoid infiltrate was mainly arranged around blood 
vessels, but additionally a focal interstitial component was present. Eosinophilic granulocytes 
and plasma cells were not found.  
 
Immunohistochemical features 
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Both intraepidermal and intradermal lymphocytes expressed CD2, CD3, and beta-F1, but 
intraepidermal lymphocytes were negative for CD4 and CD8 (Figs 4, 5). Approximately 70% 
of the intrapeidermal lymphocytes expressed CD7. More than 90% of the intraepidermal 
lymphocytes expressed PD-1 and less than 10% showed reactivity for CXCL-13 (Fig 5). Bcl-
6 was expressed by 30% of the intraepidermal lymphocytes. The lymphocytes located in the 
epidermis were negative for CD45RO, whereas the dermal lymphocytes expressed CD45RO 
and CD4. CD8 and FOXP3 stained a few dermal lymphocytes, whereas no immunopositivity 
for the two markers was seen in the epidermal component. CD10, CD20, CD30, CD45RA, 
CD56 and TIA, perforin and granzyme B were not expressed. MUM1 labeled few 
lymphocytes both in the epidermal and dermal component. Staining for T-cell receptor (TCR) 
delta chain and in situ hybridization for EBV (EBER) were negative.  
 
Molecular biological assays 
T-cell receptor (TCR) rearrangement studies were performed using a multiplex polymerase 
chain reaction (PCR) with denaturing gradient gel electrophoresis as described elsewhere (9) 
and revealed a monoclonal rearrangement of TCR gamma genes.  
 
Discussion 
The spectrum of CD4/CD8 double negative cutaneous T-cell lymphomas reported in the 
literature encompasses MF, pagetoid reticulosis, gamma/delta-positive cutaneous T-cell 
lymphoma, HTLV-1 associated adult T-cell lymphoma/leukemia, and cases which can be 
classified as cutaneous peripheral T-cell lymphoma, unspecified according to the WHO 
classification (2008; 4th edition) (10), (11),  (12), (13), (14), (15)  . Less than 35 cases of 
CD4/CD8 double negative early MF have been reported since the first description in 1993 by 
Ralfkiaer and coworkers (16), (17),  (3) , (18), (19) Our case supports the observation of 
Hodak et al that CD4/CD8 double negative MF is often associated with an unusual clinical 
presentation as in our patient in whom CD4/CD8 double negative MF clinically presented 
with annular and centrally hypopigmented lesions confined to the left lower leg as one body 
region also referred to as localized MF. Except for the expression of CD30 in early MF, none 
of the phenotypic MF variants appears to be of prognostic significance. (20). Due to the fact 
that cases of CD4/CD8 double negative MF had not been recognized prior to their work, 
Hodak et al considered the possibility that this variant of MF might be unique to the Middle 
East. (3) Our patient is of Swiss origin. In conjunction with previous reports our observation 
confirms that CD4/CD double negative MF occurs also in countries of central/western 
Europe. (16), (17), (19).  
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In contrast to the majority of the previously reported cases of CD4/CD8 double negative MF 
cases, the intraepidermal CD4 and CD8 negative tumor cells in our patient did not express 
cytotoxic molecules (TIA-1, granzyme B, perforin) indicating that the tumor cells do not 
belong to cytotoxic T-cells. The classic CD4+ form of MF is considered to represent a 
neoplasm derived from memory T helper cells. (21) The cellular origin of CD4/CD8 double 
negative MF, however, is unknown. In our case, the intraepidermal CD4/CD8 double negative 
clonal lymphocytes expressed PD-1. PD-1 expression in CTCL including MF has little been 
investigated to date and the results appears controversial. Roncandor et al found PD-1 
positivity was found in 4 out of 5 cases (80%). In contrast, Wada et al detected PD-1 
immunoreactivity only 15 of 30 MF cases (50%). (8),  (22) In two most recent articles, 
Cetinözman et al. reported PD-1 in only a subset of 2 out of 21 MF cases (9%) (23), whereas 
Kantekure et al detected PD-1 positive T cells  in all 9 patch and plaque MF cases, with 7 of 
the 9 cases showing more than 25% of the atypical lymphocytes expressing PD-1. (24) These 
differences may be due to different antibodies and immunohistochemical protocols well as 
due to different cut-off levels for positivity. There was no specification as to whether these 
cases manifested the usual and most common CD4+CD8- phenotype.  
 
Expression of PD-1 characterizes follicular helper T cells (TFH), which are normally present in 
germinal centers and possess helper function for B-cells. (4) PD-1 is expressed on activated T 
cells and B cells. PD-1 is a negative regulator of T cell activation and proliferation that 
mediates suppressive action by binding to its ligands PD-L1 and PD-L2. (25) In the context of 
lymphomas, PD-1 cells have been found to be expressed in nodal angioimmunoblastic T-cell 
lymphoma and in primary cutaneous lymphomas classified as CD4+SMPTL and identical 
lesions diagnosed by others as pseudolymphomatous folliculitis or nodular T-cell 
pseudolymphoma. (7), (26), (6) It can be speculated that CD4/CD8 double negative MF 
represents a neoplastic counterpart of TFH cells. Alternatively, expression of PD-1 may be 
upregulated as the result of activation of antigen-stimulated T cells with loss of CD4 and CD8 
since PD-1 can be expressed on activated T-cells. Remarkably, the PD-1 positive tumor cells 
in our case did not show expression of CXCL-13 and bcl-6 only in 30%, whereas tumor cells 
in cutaneous CD4+ SMPTL express both markers. (6) The lack of expression of CXCL-13 
and CD10 as markers expressed by follicular T helper cells under physiological conditions 
may be suggestive of a possible origin of this unusual variant of MF from neoplastic follicular 
T helper cells. 
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The CD4/CD8 double negative phenotype in MF appears to have no prognostic significance, 
as so far reported cases showed an indolent course. (3) This is important as the differential 
diagnosis includes a heterogeneous group of other CTCL with CD4/CD8 double negative 
phenotype characterized by an aggressive clinical course. (13) Based on the clinical, 
histological and phenotypic findings, cutaneous gamma/delta lymphoma, peripheral T-cell 
lymphoma not otherwise unspecified (NOS), and infiltrates of angioimmunoblastic T-cell 
lymphoma could be excluded as differential diagnoses in our patient. The absence of 
eosinophilic granulocytes, the negative patch test, the phenotype of lymphocytes as well as 
the detection of clonal T-cells argue against lymphomatoid contact dermatitis.  
 
Although our observation is limited to a single case, it may give insight into the histogenesis 
of this MF variant and indicate the direction for future studies in the field. The findings will 
also be of therapeutic significance since PD-1 may serve as an interesting target for 
therapeutic intervention. (25) 
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Figure legends: 
 
Figure 1: 
Annular and hypopigmented patches on the left lower leg. 
 
Figure 2: 
Epidermis infiltrated by small lymphocytes with chromatin dense nuclei. H&E, original 
magnification, 100X 
 
Figure 3: Intraepidermal lymphocytes show nuclear atypia. H&E, original magnification, 
200X 
 
Figure 4: 
Both intraepidermal and intradermal lymphocytes express CD3, Immunohistochemistry, 
original magnification, 100X 
 
Figure 5: 
A. Intraepidermal and intradermal lymphocytes express beta-F1. B. Lack of expression of 
CD4 by intraepidermal lymphocytes. C. Intraepidermal lymphocytes are negative for 
CD8. D. Intraepidermal lymphocytes express PD-1. (Immunohistochemistry, original 
magnification, 100X A-D) 
 
 
